Mitiglinide calcium hydrate (KAD-1229) is an insulinotropic agent. Mitiglinide calcium hydrate is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide is a drug for the treatment of type 2 diabetes. It may stimulate insulin secretion in beta-cells by closing off ATP dependant potassium ion channels.
KAD-1229 Calcium Hydrate (Mitiglinide calcium dihydrate) could binds to sulfonylurea receptors and inhibits the activity of ATP-sensitive K+ channel in MIN 6 cells. Antidiabetic.
Mitiglinide is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) (K(ATP)) channels in pancreatic beta-cells, and its early insulin release and short duration of action would be effective in improving postprandial hyperglycemia.
